---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-022205"
form_type: "8-K"
ticker: "SNES"
cik: "0001680378"
company_name: "SenesTech, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:21:44.660337+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SenesTech Q1 revenue $415K record, up 78% YoY; Evolve drives >50% of sales

## Summary
- Q1 2024 revenue $415,000, up 78% from $233,000 in Q1 2023; record quarterly revenue.
- Net loss narrowed to $1.8M from $2.0M; adjusted EBITDA loss $1.7M vs $1.8M.
- Evolve soft bait accounted for >50% of Q1 revenue; became biggest-selling product.
- Launched Evolve Mouse in May 2024; extended distribution to Amazon, rep groups, 4,500 retail locations.
- Cash at March 31, 2024 was $3.6M; New York City Council proposed deploying EPA-approved rat birth control.

## SEC filing metadata
- accession: 0001628280-24-022205
- form_type: 8-K
- ticker: SNES
- cik: 0001680378
- company_name: SenesTech, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680378/000162828024022205/0001628280-24-022205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680378/000162828024022205/snes-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-022205
- JSON: https://secwatch.observer/filing/0001628280-24-022205.json
- Plain text: https://secwatch.observer/filing/0001628280-24-022205.txt

## Key facts
- Earnings Releases
  SenesTech, Inc. reported first quarter ended March 31, 2024 results: revenue $415,000, net income $1.8 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $415,000
  - Net income: $1.8 million
  - Result: reported results
  source text: EPA-registered Rat Birth Control ® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • EvolveTM, formulated especially for the control of rat fertility and launched at the beginning of the year, has quickly become the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680378/000162828024022205/0001628280-24-022205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.